OncoCyte (OCX) Upgraded by Zacks Investment Research to Buy

OncoCyte (NYSEAMERICAN:OCX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday. The firm presently has a $5.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 13.64% from the company’s current price.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

Separately, ValuEngine lowered shares of OncoCyte from a “hold” rating to a “sell” rating in a report on Thursday, October 5th.

OncoCyte (NYSEAMERICAN OCX) opened at $4.40 on Friday. The stock has a market cap of $138.28 and a PE ratio of -7.10. OncoCyte has a 1-year low of $3.60 and a 1-year high of $7.85.

An institutional investor recently raised its position in OncoCyte stock. Broadwood Capital Inc. grew its stake in shares of OncoCyte Co. (NYSEAMERICAN:OCX) by 17.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,596,680 shares of the biotechnology company’s stock after acquiring an additional 540,000 shares during the quarter. OncoCyte comprises about 4.5% of Broadwood Capital Inc.’s holdings, making the stock its 5th largest position. Broadwood Capital Inc. owned 11.48% of OncoCyte worth $27,155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/06/oncocyte-ocx-upgraded-by-zacks-investment-research-to-buy.html.

OncoCyte Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Get a free copy of the Zacks research report on OncoCyte (OCX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply